This database contains 168 studies, archived under the term: "adverse effects"
Click here to filter this large number of results.
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Study of the effects of vinpocetin on cognitive functions
Introduction: Chronic cerebral hypoperfusion is a risk factor for the development of certain types of dementia. Mild cognitive impairment is a stage of predementia condition, because the symptoms are similar but not as severe as the symptoms in patients with dementia. Vinpocetine, due to its complex mechanism of action, has an important role in the […]
Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer’s disease
Human granulocyte colony-stimulating-factor (G-CSF) is widely used for treatment of neutropenia and to mobilize stem/progenitor cells for bone marrow transplantation. In studies of thousands of healthy donor subjects treated with G-CSF to mobilize stem/progenitor cells, the side-effect profile has been reported to be mild and reversible. In pre-clinical studies, G-CSF was reported to improve spatial […]
Alzheimer’s disease: is pacemaker implantation safe?
Aim: To evaluate the safety of pacemaker implantation in patients with Alzheimer’s disease (AD).; Methods: We reviewed all cases admitted to our institution between January 2008 and June 2009, with symptomatic bradyarrhythmia for whom a permanent pacemaker was implanted. Beginning in June 2009, we prospectively collected data from all patients with the same diagnosis and […]
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]